Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue.

Thyrotropin-secreting pituitary adenomas are aggressive, invasive tumors that respond poorly to available surgical and medical treatments. Inappropriate release of thyrotropin by these tumors can result in hyperthyroidism. We treated five patients who had thyrotropin-secreting pituitary adenomas with the long-acting somatostatin analogue SMS 201-995, which was administered by subcutaneous injection in doses of 50 to 100 micrograms every 8 to 12 hours. Serum levels of thyrotropin were dramatically reduced by treatment in four of the five patients, and levels of another tumor marker, the alpha-subunit of thyrotropin, were reduced in all five. In two patients with hyperthyroidism due to production of excess thyrotropin by the tumor, treatment with the somatostatin analogue resulted in a sustained euthyroid state. One patient who was treated for more than 16 months had a persistent reduction in serum levels of thyrotropin and iodothyronines. We conclude that SMS 201-995 is an effective means of controlling hypersecretion of thyrotropin and the associated hyperthyroidism due to thyrotropin-secreting pituitary tumors.

[1]  O. Owen,et al.  Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995. , 1986, The New England journal of medicine.

[2]  D. Ross.  New Sensitive lmmunoradiometric Assays for Thyrotropin , 1986 .

[3]  S. Lamberts,et al.  Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. , 1985, The New England journal of medicine.

[4]  G. Spinas,et al.  Reduced Postprandial Hyperglycemia After Subcutaneous Injection of a Somatostatin-Analogue (SMS 201-995) in Insulin-dependent Diabetes Mellitus , 1985, Diabetes Care.

[5]  K. Osei,et al.  Malignant insulinoma: effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones. , 1985, Annals of internal medicine.

[6]  A. Pinchera,et al.  In vitro studies on TSH secretion and adenylate cyclase activity in a human TSH-secreting pituitary adenoma. Effects of somatostatin and dopamine , 1985, Journal of endocrinological investigation.

[7]  B. Weintraub,et al.  Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone. , 1985, The New England journal of medicine.

[8]  R. Jensen,et al.  Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. , 1985, The New England journal of medicine.

[9]  G. Beckett,et al.  A sensitive immunoradiometric assay for serum thyroid stimulating hormone: a replacement for the thyrotrophin releasing hormone test? , 1984, British medical journal.

[10]  J. Beyer,et al.  LONG-ACTING AND SELECTIVE SUPPRESSION OF GROWTH HORMONE SECRETION BY SOMATOSTATIN ANALOGUE SMS 201-995 IN ACROMEGALY , 1984, The Lancet.

[11]  W. E. Cobb,et al.  Use of a rapid, sensitive immunoradiometric assay for thyrotropin to distinguish normal from hyperthyroid subjects. , 1984, Clinical chemistry.

[12]  K. Kuma,et al.  Bromocriptine therapy for hyperthyroidism due to increased thyrotropin secretion. , 1984, The Journal of clinical endocrinology and metabolism.

[13]  H. Gharib,et al.  Pituitary thyrotropic adenoma associated with congenital hypothyroidism. Report of two cases. , 1984, The American journal of medicine.

[14]  K. McCormick,et al.  Thyrotropin (TSH)-induced hyperthyroidism: response of TSH to dopamine and its agonists. , 1984, The Journal of clinical endocrinology and metabolism.

[15]  B. Weintraub,et al.  Naturally occurring forms of thyrotropin with low bioactivity and altered carbohydrate content act as competitive antagonists to more bioactive forms. , 1983, Endocrinology.

[16]  M. Cattaneo,et al.  Successful treatment of hyperthyroidism due to nonneoplastic pituitary TSH hypersecretion with 3,5,3′-triiodothyroacetic acid (TRIAC) , 1983, Journal of endocrinological investigation.

[17]  R. Fahlbusch,et al.  HYPERTHYROIDISM DUE TO A TSH SECRETING PITUITARY ADENOMA: CASE REPORT, TREATMENT AND EVIDENCE FOR ADENOMA TSH BY MORPHOLOGICAL AND CELL CULTURE STUDIES , 1983, Clinical endocrinology.

[18]  P. Marbach,et al.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. , 1982, Life sciences.

[19]  B. Weintraub,et al.  Heterogeneous forms of thyroid-stimulating hormone in mouse thyrotropic tumor and serum: differences in receptor-binding and adenylate cyclase-stimulating activity. , 1981, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[20]  B. Weintraub,et al.  Inappropriate secretion of thyroid-stimulating hormone. , 1981, Annals of internal medicine.

[21]  L. Orci,et al.  Somatostatinoma syndrome. Biochemical, morphologic and clinical features. , 1979, The New England journal of medicine.

[22]  P. Gorden,et al.  Conventional supervoltage irradiation is an effective treatment for acromegaly. , 1979, The Journal of clinical endocrinology and metabolism.

[23]  B. Osborne,et al.  Endocrine and morphologic studies of pituitary adenomas secondary to primary hypothyroidism , 1977 .

[24]  B. Weintraub,et al.  Thyrotropin-induced hyperthyroidism: use of alpha and beta subunit levels to identify patients with pituitary tumors. , 1977, The Journal of clinical endocrinology and metabolism.

[25]  G. Giustina,et al.  Hyperthyroidism with elevated plasma TSH levels and pituitary tumor: study with somatostatin. , 1976, The Journal of clinical endocrinology and metabolism.

[26]  W. Florsheim,et al.  Physiological modulation of thyrotropin secretion by somatostatin and thyroliberin. , 1976, Biochemical and biophysical research communications.

[27]  A. Schally,et al.  Increase in basal and thyrotropin-releasing hormone (TRH)-stimulated secretion of thyrotropin (TSH) by passive immunization with antiserum to somatostatin in rats. , 1976, Endocrinology.

[28]  M. Jobin,et al.  Physiological role of somatostatin in the control of growth hormone and thyrotropin secretion. , 1976, Biochemical and biophysical research communications.

[29]  A. P. Hansen,et al.  Inhibition by somatostatin of basal levels of serum thyrotropin (TSH) in normal men. , 1975, The Journal of clinical endocrinology and metabolism.

[30]  R. Guillemin,et al.  Effects of somatostatin on the secretion of thyrotropin and prolactin. , 1974, Endocrinology.

[31]  R. Guillemin,et al.  Inhibition by somatostatin on the release of TSH induced in man by thyrotropin-releasing factor. , 1974, The Journal of clinical endocrinology and metabolism.

[32]  F. Maloof,et al.  Hyperthyroidism due to thyrotropin-producing pituitary chromophobe adenoma. , 1970, The New England journal of medicine.

[33]  C. Hales,et al.  Labelled Antibodies and Immunological Assay Systems , 1968, Nature.

[34]  P. Gorden,et al.  The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly. , 1987, The Journal of clinical endocrinology and metabolism.

[35]  B. Weintraub,et al.  TSH-Secreting Pituitary Tumors , 1986 .

[36]  D. Reid,et al.  Standards for the basal metabolism of normal people in Britain. , 1952, Lancet.